- Home
- FAMI vs AZTR Comparison
FAMI vs AZTR Comparison
Compare FAMI & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAMI
- AZTR
- Stock Information
- Founded
- FAMI 2015
- AZTR 2014
- Country
- FAMI China
- AZTR United States
- Employees
- FAMI N/A
- AZTR N/A
- Industry
- FAMI Packaged Foods
- AZTR Biotechnology: Pharmaceutical Preparations
- Sector
- FAMI Consumer Staples
- AZTR Health Care
- Exchange
- FAMI Nasdaq
- AZTR Nasdaq
- Market Cap
- FAMI 3.1M
- AZTR 3.2M
- IPO Year
- FAMI 2018
- AZTR 2023
- Fundamental
- Price
- FAMI $0.24
- AZTR $0.31
- Analyst Decision
- FAMI
- AZTR
- Analyst Count
- FAMI 0
- AZTR 0
- Target Price
- FAMI N/A
- AZTR N/A
- AVG Volume (30 Days)
- FAMI 5.6M
- AZTR 4.7M
- Earning Date
- FAMI 02-14-2025
- AZTR 03-14-2025
- Dividend Yield
- FAMI N/A
- AZTR N/A
- EPS Growth
- FAMI N/A
- AZTR N/A
- EPS
- FAMI N/A
- AZTR N/A
- Revenue
- FAMI $64,131,332.00
- AZTR $97,500.00
- Revenue This Year
- FAMI N/A
- AZTR N/A
- Revenue Next Year
- FAMI N/A
- AZTR N/A
- P/E Ratio
- FAMI N/A
- AZTR N/A
- Revenue Growth
- FAMI N/A
- AZTR N/A
- 52 Week Low
- FAMI $0.17
- AZTR $0.23
- 52 Week High
- FAMI $2.35
- AZTR $38.10
- Technical
- Relative Strength Index (RSI)
- FAMI 37.45
- AZTR 44.00
- Support Level
- FAMI $0.29
- AZTR $0.24
- Resistance Level
- FAMI $0.27
- AZTR $0.35
- Average True Range (ATR)
- FAMI 0.04
- AZTR 0.04
- MACD
- FAMI -0.01
- AZTR -0.00
- Stochastic Oscillator
- FAMI 6.10
- AZTR 13.58
About FAMI Farmmi Inc.
Farmmi Inc is a supplier of agricultural products. The products of the company are Shiitake Mushroom, Mu Er Mushroom and other edible fungi and other agricultural products. The majority of products are sold in mainland China.
About AZTR Azitra Inc
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. The company has built a proprietary platform that includes a microbial library comprised of bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains.